You can buy Luciupa at the lowest price at Nextgen.ooo online pharmacy. Upadacitinib is an orally active, selective Janus kinase (JAK)1 inhibitor and disease-modifying antirheumatic drug (DMARD) that is used in the treatment of rheumatoid arthritis to slow the progression of the disease. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage, and bone destruction, leading to comorbidities. Despite the variety of therapeutic agents available for treatment, up to 40% of patients do not respond to current therapies, including biological therapies. The etiology of the disease is largely unknown; however, the role of JAK as a driver of immune-mediated conditions has been discovered, leading to the use of JAK as therapeutic targets in rheumatoid arthritis.
 
More selective JAK1 inhibitors, upadacitinib and filgotinib, have been developed to reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy. The FDA approved upadacitinib in August 2019 and it is used to treat active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. It was further approved by the European Commission in December 2019.